Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).

BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)

BAY1000394 (2.5mg)

BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)

BAY1000394 (5mg)

Bayer Study Director

This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.

Japanese BAY1000394 Monotherapy Phase I Study

An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies

Bayer

All Drugs and Chemicals

Cyclin-Dependent Kinase Inhibitor Proteins

BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.

BAY1000394

Clinical study to determine safety, tolerability, and maximum tolerated dose of BAY1000394 given in 4 week on / 2 week off schedule to patients with advanced solid tumors

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Japanese BAY1000394 Monotherapy Phase I Study	NCT02047890	Neoplasms	BAY1000394 (2.5... BAY1000394 (5mg...	20 Years -	Bayer
Japanese BAY1000394 Monotherapy Phase I Study	NCT02047890	Neoplasms	BAY1000394 (2.5... BAY1000394 (5mg...	20 Years -	Bayer
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies	NCT01335256	Neoplasms	BAY1000394	18 Years -	Bayer

Spots Global Cancer Trial Database for bay1000394

Every month we try and update this database with for bay1000394 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bay1000394

Every month we try and update this database with for bay1000394 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bay1000394 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.